Antiphospholipid Syndrome

As per available reports about 20 journals, 1 Conference are presently dedicated exclusively to Antiphospholipid syndrome and about 2794 articles are being published on the current trends in Antiphospholipid syndrome. In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to proteomics are being carried out. Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS or), often also Hughes syndrome, is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies. When antibodies attack phospholipids, cells are damaged. This damage causes blood clots to form in the body's arteries and veins.

The Journal of Clinical & Cellular Immunology is an academic journal – hosted by OMICS International – a pioneer in open access publishing–and is listed among the top 10 journals in Antiphospholipid syndrome. Each year research scientists have noticed a rise in the number of congresses being held in this field. The Journal of Clinical & Cellular Immunology provides a unique platform to researchers and scientist to explore the advanced and latest research developments in the field of Antiphospholipid syndrome, thus bridging the gap between researchers and young scientists.

OMICS Group, the world pioneer for organizing 150 International conferences in USA, Europe, Asia and other continents. Uniquely, 350 peer-reviewed open access journals were operating by OMICS International. This will reflect the scope in current research and development in science, healthcare and technology. With a strong intention to accelerate the scientific discovery, OMICS Group International has been associated with more than150 scientific Societies and Associations.